Literature DB >> 34290447

Molecular events in neuroendocrine prostate cancer development.

Yong Wang1,2,3, Yu Wang1,2,4, Xinpei Ci1,2,4, Stephen Y C Choi1,2,4, Francesco Crea5, Dong Lin6,7,8, Yuzhuo Wang9,10,11.   

Abstract

Neuroendocrine prostate cancer (NEPC) is a lethal subtype of prostate cancer. NEPC arises de novo only rarely; the disease predominantly develops from adenocarcinoma in response to drug-induced androgen receptor signalling inhibition, although the mechanisms behind this transdifferentiation are a subject of debate. The survival of patients with NEPC is poor, and few effective treatment options are available. To improve clinical outcomes, understanding of the biology and molecular mechanisms regulating NEPC development is crucial. Various NEPC molecular drivers make temporal contributions during NEPC development, and despite the limited treatment options available, several novel targeted therapeutics are currently under research.
© 2021. Springer Nature Limited.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34290447     DOI： 10.1038/s41585-021-00490-0

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


  164 in total

1.  Abiraterone and increased survival in metastatic prostate cancer.

Authors:  Johann S de Bono; Christopher J Logothetis; Arturo Molina; Karim Fizazi; Scott North; Luis Chu; Kim N Chi; Robert J Jones; Oscar B Goodman; Fred Saad; John N Staffurth; Paul Mainwaring; Stephen Harland; Thomas W Flaig; Thomas E Hutson; Tina Cheng; Helen Patterson; John D Hainsworth; Charles J Ryan; Cora N Sternberg; Susan L Ellard; Aude Fléchon; Mansoor Saleh; Mark Scholz; Eleni Efstathiou; Andrea Zivi; Diletta Bianchini; Yohann Loriot; Nicole Chieffo; Thian Kheoh; Christopher M Haqq; Howard I Scher
Journal:  N Engl J Med       Date:  2011-05-26       Impact factor: 91.245

Review 2.  Histological variants of prostatic carcinoma and their significance.

Authors:  Peter A Humphrey
Journal:  Histopathology       Date:  2012-01       Impact factor: 5.087

3.  Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate.

Authors:  C Huggins; C V Hodges
Journal:  CA Cancer J Clin       Date:  1972 Jul-Aug       Impact factor: 508.702

4.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

5.  Abiraterone in metastatic prostate cancer without previous chemotherapy.

Authors:  Charles J Ryan; Matthew R Smith; Johann S de Bono; Arturo Molina; Christopher J Logothetis; Paul de Souza; Karim Fizazi; Paul Mainwaring; Josep M Piulats; Siobhan Ng; Joan Carles; Peter F A Mulders; Ethan Basch; Eric J Small; Fred Saad; Dirk Schrijvers; Hendrik Van Poppel; Som D Mukherjee; Henrik Suttmann; Winald R Gerritsen; Thomas W Flaig; Daniel J George; Evan Y Yu; Eleni Efstathiou; Allan Pantuck; Eric Winquist; Celestia S Higano; Mary-Ellen Taplin; Youn Park; Thian Kheoh; Thomas Griffin; Howard I Scher; Dana E Rathkopf
Journal:  N Engl J Med       Date:  2012-12-10       Impact factor: 91.245

Review 6.  Aggressive variants of castration-resistant prostate cancer.

Authors:  Himisha Beltran; Scott Tomlins; Ana Aparicio; Vivek Arora; David Rickman; Gustavo Ayala; Jiaoti Huang; Lawrence True; Martin E Gleave; Howard Soule; Christopher Logothetis; Mark A Rubin
Journal:  Clin Cancer Res       Date:  2014-04-11       Impact factor: 12.531

7.  Molecular determinants of resistance to antiandrogen therapy.

Authors:  Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers
Journal:  Nat Med       Date:  2003-12-21       Impact factor: 53.440

Review 8.  Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer.

Authors:  Philip A Watson; Vivek K Arora; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2015-11-13       Impact factor: 60.716

9.  Enzalutamide in metastatic prostate cancer before chemotherapy.

Authors:  Tomasz M Beer; Andrew J Armstrong; Dana E Rathkopf; Yohann Loriot; Cora N Sternberg; Celestia S Higano; Peter Iversen; Suman Bhattacharya; Joan Carles; Simon Chowdhury; Ian D Davis; Johann S de Bono; Christopher P Evans; Karim Fizazi; Anthony M Joshua; Choung-Soo Kim; Go Kimura; Paul Mainwaring; Harry Mansbach; Kurt Miller; Sarah B Noonberg; Frank Perabo; De Phung; Fred Saad; Howard I Scher; Mary-Ellen Taplin; Peter M Venner; Bertrand Tombal
Journal:  N Engl J Med       Date:  2014-06-01       Impact factor: 91.245
View more
  10 in total

Review 1.  Advances in neuroendocrine prostate cancer research: From model construction to molecular network analyses.

Authors:  Xue Shui; Rong Xu; Caiqin Zhang; Han Meng; Jumei Zhao; Changhong Shi
Journal:  Lab Invest       Date:  2021-12-22       Impact factor: 5.662

Review 2.  Anti-Androgen Receptor Therapies in Prostate Cancer: A Brief Update and Perspective.

Authors:  Jian Huang; Biyun Lin; Benyi Li
Journal:  Front Oncol       Date:  2022-03-10       Impact factor: 6.244

Review 3.  Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer.

Authors:  Juan C Pardo; Vicenç Ruiz de Porras; Joan Gil; Albert Font; Manel Puig-Domingo; Mireia Jordà
Journal:  Nutrients       Date:  2022-02-18       Impact factor: 5.717

Review 4.  New Insights and Emerging Therapeutic Approaches in Prostate Cancer.

Authors:  Fabrizio Licitra; Pia Giovannelli; Marzia Di Donato; Alessandra Monaco; Giovanni Galasso; Antimo Migliaccio; Gabriella Castoria
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-11       Impact factor: 5.555

5.  miR-145-5p Inhibits Neuroendocrine Differentiation and Tumor Growth by Regulating the SOX11/MYCN Axis in Prostate cancer.

Authors:  Shuya Ji; Yi Shi; Lin Yang; Feng Zhang; Yong Li; Feng Xu
Journal:  Front Genet       Date:  2022-03-09       Impact factor: 4.599

Review 6.  Immunotherapy of Neuroendocrine Neoplasms: Any Role for the Chimeric Antigen Receptor T Cells?

Authors:  Giuseppe Fanciulli; Roberta Modica; Anna La Salvia; Federica Campolo; Tullio Florio; Nevena Mikovic; Alice Plebani; Valentina Di Vito; Annamaria Colao; Antongiulio Faggiano
Journal:  Cancers (Basel)       Date:  2022-08-18       Impact factor: 6.575

7.  Transcriptional profiling of matched patient biopsies clarifies molecular determinants of enzalutamide-induced lineage plasticity.

Authors:  Thomas C Westbrook; Xiangnan Guan; Eva Rodansky; Diana Flores; Chia Jen Liu; Aaron M Udager; Radhika A Patel; Michael C Haffner; Ya-Mei Hu; Duanchen Sun; Tomasz M Beer; Adam Foye; Rahul Aggarwal; David A Quigley; Jack F Youngren; Charles J Ryan; Martin Gleave; Yuzhuo Wang; Jiaoti Huang; Ilsa Coleman; Colm Morrissey; Peter S Nelson; Christopher P Evans; Primo Lara; Robert E Reiter; Owen Witte; Matthew Rettig; Christopher K Wong; Alana S Weinstein; Vlado Uzunangelov; Josh M Stuart; George V Thomas; Felix Y Feng; Eric J Small; Joel A Yates; Zheng Xia; Joshi J Alumkal
Journal:  Nat Commun       Date:  2022-09-15       Impact factor: 17.694

Review 8.  To bind or not to bind: Cistromic reprogramming in prostate cancer.

Authors:  Michelle Shen; Léa-Kristine Demers; Swneke D Bailey; David P Labbé
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

9.  Neuroendocrine Carcinoma as an Independent Prognostic Factor for Patients With Prostate Cancer: A Population-Based Study.

Authors:  Jiping Yao; Yanning Liu; Xue Liang; Jiajia Shao; Yina Zhang; Jing Yang; Min Zheng
Journal:  Front Endocrinol (Lausanne)       Date:  2021-12-08       Impact factor: 5.555

10.  PAQR6 Upregulation Is Associated with AR Signaling and Unfavorite Prognosis in Prostate Cancers.

Authors:  Min Yang; Jean Chong Li; Chang Tao; Sa Wu; Bin Liu; Qiang Shu; Benyi Li; Runzhi Zhu
Journal:  Biomolecules       Date:  2021-09-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.